De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections

By Masterton Robert G.   Casamayor Montserrat   Musingarimi Primrose   van Engen Anke   Zinck Raymund   Odufowora-Sita Olatunji   Odeyemi Isaac A. O.  

Journal of Medical Economics, Vol. 16, Iss. 11, 2013-11 ,pp. : 1344-1356

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK

By Sidhu M. K.   van Engen A. K.   Kleintjens J.   Schoeman O.   Palazzo M.  

Current Medical Research and Opinion, Vol. 25, Iss. 8, 2009-08 ,pp. : 2049-2059

Informa Healthcare

Access to resources Recommend Favorite

Distribution and drug susceptibilities of Candida species causing candidemia from a medical center in central Taiwan

By Chang Te-Pin   Ho Mao-Wang   Yang Yun-Liang   Lo Pai-Chang   Lin Pei-Sheng   Wang An-Huei   Lo Hsiu-Jung  

Journal of Infection and Chemotherapy, Vol. 19, Iss. 6, 2013-12 ,pp. : 1065-1071

Springer Publishing Company

Access to resources Recommend Favorite

Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern

By Taj-Aldeen S.   Kolecka A.   Boesten R.   Alolaqi A.   Almaslamani M.   Chandra P.   Meis J.   Boekhout T.  

Infection, Vol. 42, Iss. 2, 2014-04 ,pp. : 393-404

Springer Publishing Company

Access to resources Recommend Favorite

Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins

By  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1729-1762

Informa Healthcare

Access to resources Recommend Favorite